Developing effective therapies for central nervous system (CNS) disorders is one of the most challenging tasks facing the pharmaceutical industry and the biomedical research community. In no other arena is the unmet therapeutic need as large as in CNS disorders, both in qualitative terms and demographically.

(Photo: )

Next-Generation CNS Therapeutics: An Analysis of 14 Therapeutic Pipelines, a new DR Report published by Decision Resources, analyzes the R&D strategies and business plans of 14 selected companies and presents a view of the CNS marketplace over the next decade. Based on our analysis of these companies' CNS drug development programs, we expect the next few years to be marked by the following characteristics:

  -- Psychiatric conditions will continue to be the major drivers of growth      for the CNS pharmaceutical market until 2005 and beyond.   -- Drugs will enter the market that are selective for those receptor      subunits that mediate the desired activity or for subtypes of receptors      that today's drugs only broadly address.   -- The first CNS drugs will emerge that are designed to act on      nonconventional (but already known) drug targets, such as signaling      systems based on neuropeptides or nitric oxide.   -- Genomics and proteomics projects, including gene therapy research, will      validate presently unknown drug targets.  

Until recently, large pharmaceutical companies have dominated this market; however, most of the innovation seen today in this sector is led by small, emerging players. To provide a balanced view of the current CNS drug development landscape, we evaluate three tiers of companies in this report: Seven major pharmaceutical market leaders: Aventis, GlaxoSmithKline, Merck & Co., Novartis, Pfizer, Roche, and Wyeth-Ayerst.

Two midsize players: Lundbeck and Shire Pharmaceuticals Group. Five emerging CNS specialist companies: Axonyx, Cephalon, Guilford Pharmaceuticals, Neurobiological Technologies, and Neurocrine Biosciences.

Next-Generation CNS Therapeutics: An Analysis of 14 Therapeutic Pipelines is a DR Report published by Decision Resources, Inc. This report is available for $5,000.00.

Decision Resources, Inc., is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at

Contact Tim Daley, 781.296.2636 (tel), 781.296.2550 (fax), or

In Europe, contact Francoise Bidart, +32.2.351.4082 (tel), +32.2.351.2347 (fax), or

In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (tel), +81.3.5401.2617 (fax), or



AP Archive:

PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Tim Daley of Decision Resources, +1-781-296-2636,

Decision Resources Study Finds Protein-Kinase-C Inhibitors Have Significant Market Potential in the Treatment of Diabetic Retinopathy

View Now